Caribou Biosciences Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

CRBU$0.41-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Licensing and collaboration revenue (including $2,245 and $2,867 for three and six months ended June 30, 2024, respectively, and $1,150 for each of the three- and six-month periods ended June 30, 2023, from related parties)	$3,464	$3,755	$5,893	$7,257
Operating expenses:
Research and development	35,480	26,503	69,268	52,212
General and administrative	11,485	10,120	26,128	19,029
Total operating expenses	46,965	36,623	95,396	71,241
Loss from operations	(43,501)	(32,868)	(89,503)	(63,984)
Other income (expense):
Change in fair value of equity securities	(102)	22	(102)	7
Change in fair value of the MSKCC success payments liability	1,795	279	2,098	534
Other income, net	4,111	3,048	8,576	5,880
Total other income	5,804	3,349	10,572	6,421
Net loss	(37,697)	(29,519)	(78,931)	(57,563)
Other comprehensive income (loss):
Net unrealized (loss) gain on available-for-sale marketable securities, net of tax	3	(406)	(349)	382
Net comprehensive loss	$(37,694)	$(29,925)	$(79,280)	$(57,181)
Net loss per share, basic and diluted	$(0.42)	$(0.48)	$(0.88)	$(0.94)
Weighted-average common shares outstanding, basic and diluted	90,340,932	61,417,934	89,821,935	61,302,863

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.